Consistent Revenue and Healthy Gross Margin
CV Sciences achieved a revenue of $3.9 million with a gross margin of 46%, consistent with previous quarters, maintaining their position in a competitive market.
Market Leadership and New Product Launch
The company maintained its #1 position in the natural product retail channel and launched +PlusHLTH, a new line of cannabinoid-free supplements with positive initial reception.
Successful M&A Strategy
CV Sciences completed acquisitions of Elevated Softgels and Cultured Foods, contributing to increased capability, scale, and anticipated cost efficiencies.
Strong B2C Performance
Direct-to-consumer business represented 42.8% of total revenue in Q3 2024, showing an increase from 40.9% a year earlier, despite a competitive market and reduced marketing spend.